LUCID
Value Proposition
IRL technology has a variety of clinical advantages, including the potential to treat multiple types of TBI non-invasively. Mitochondrial dysfunction has been found to be a significant factor in the progression of secondary brain injury. LUCID efficiently and safely delivers deeply penetrating infrared light (IRL) of a specific wavelength combination shown to effectively prevent the formation of toxic free radicals in the brain following TBI.
Competitive Advantage
The infrared light treatment device will efficiently and safely deliver deeply penetrating infrared light (IRL) of a specific wavelength combination shown to effectively prevent the formation of toxic free radicals in the brain following TBI.
The delivery interface is capable of non-invasively delivering therapeutic light into the human brain and is easy to deploy at the bedside and/or in the field.
Unique Features
Completely Non-Invasive
Easy to Deploy at the Bedside and in the Field
Delivers Therapeutic Light Deeply into Brain
Safe and Efficient
Licensing Information
Mitovation in 2018
Principal Investigators
Tom Sanderson, PhD
Joe Wider, PhD
Intellectual Property
Invention Disclosure # 2019-293, 2021-403
Solution Sheet
Download Solution Sheet (PDF)
Image courtesy of project team
Together with existing feasibility, safety and efficacy studies, IRL can provide a robust and safe treatment option for any head trauma, irrespective of the heterogeneous nature of TBI. In addition to the >5,500 hospitals in the US, this device can be used in non-hospital facilities, such as schools, athletic buildings and in combat territories.
By applying a novel therapeutic technology, infrared light (IRL) irradiation, this device can target the cellular injury processes following head trauma. Based on the molecular events that contribute to the secondary injury of TBI, IRL will reduce cell death and improve recovery by treating the early stages (up to 4 hours) following TBI.
Contact Mitovation for more information about investment and partnership opportunities.
Funding History
$491,211 in non-dilutive funding
2018 $99,686 Massey Grand Challenge
2019 $182,841 Massey Grand Challenge
2019 $40,000 Schwabauer Accelerator Award
2020 $170,939 NIH
2020 $135,109 Massey Grand Challenge
2021 $168,948 Massey Grand Challenge
2021 $40,000 Schwabauer Accelerator Award
2022 $154,219 Massey Grand Challenge
Substantial additional departmental, school and center based support
Funding Organizations
